Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melanie Senior

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Nature Biotechnology|May 17, 2020
Biotech companies prepare for COVID-19 downturnMelanie Senior
Nature Biotechnology|May 10, 2014
Going it aloneMelanie Senior
Nature Biotechnology|October 10, 2014
The price of priority review: $67.5 millionMelanie Senior
Nature Biotechnology|January 11, 2018
Texas displays 'Silicon Valley' credentials to lure Brazilian biotechsMelanie Senior
Nature Biotechnology|November 4, 2022
Pharma backs off biotech acquisitionsMelanie Senior
Nature Biotechnology|April 6, 2018
Rollout of high-priced cell and gene therapies forces payer rethinkMelanie Senior
Nature Biotechnology|June 6, 2023
After GLP-1, what's next for weight loss?Melanie Senior
Nature Biotechnology|May 26, 2026
Programming biology: next-gen AI firms raise billions to design better medicinesMelanie Senior
Nature Biotechnology|February 1, 2022
Fresh from the biotech pipeline: too much, too fast?Melanie Senior
Nature Biotechnology|July 4, 2019
'Scientific wellness' searches for a business modelMelanie Senior
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Nature Biotechnology|May 17, 2020
Biotech companies prepare for COVID-19 downturnMelanie Senior
Nature Biotechnology|May 10, 2014
Going it aloneMelanie Senior
Nature Biotechnology|October 10, 2014
The price of priority review: $67.5 millionMelanie Senior
Nature Biotechnology|January 11, 2018
Texas displays 'Silicon Valley' credentials to lure Brazilian biotechsMelanie Senior
Nature Biotechnology|November 4, 2022
Pharma backs off biotech acquisitionsMelanie Senior
Nature Biotechnology|April 6, 2018
Rollout of high-priced cell and gene therapies forces payer rethinkMelanie Senior
Nature Biotechnology|June 6, 2023
After GLP-1, what's next for weight loss?Melanie Senior
Nature Biotechnology|May 26, 2026
Programming biology: next-gen AI firms raise billions to design better medicinesMelanie Senior
Nature Biotechnology|February 1, 2022
Fresh from the biotech pipeline: too much, too fast?Melanie Senior
Nature Biotechnology|July 4, 2019
'Scientific wellness' searches for a business modelMelanie Senior
Pageof 6